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Introduction
Management and control of multidrug resistant (MDR) tuberculosis, tuberculosis that is resistant 
to both isoniazid and rifampicin, relies on timely and correct diagnosis. The World Health 
Organization has endorsed the Xpert®MTB/RIF (Cepheid Sunnyvale, CA, United States) and 
GenoType MTBDRplus (HAIN Life Sciences, Nehren, Germany) tests for rapid diagnosis of MDR 
tuberculosis.1,2 For the Xpert MTB/RIF test, the current recommendation is to treat any rifampicin-
resistant individual as a case of MDR tuberculosis until proven otherwise by subsequent drug 
susceptibility testing, after which treatment is to be tailored or individualised accordingly. The 
combination of Xpert MTB/RIF and MTBDRplus test results would be a powerful tool to achieve 
prompt confirmation of diagnosis of MDR tuberculosis. These genotypic methods, however, do 
not detect resistance conferred by mutations outside of the targeted gene region.3,4,5
We report comparative observations made in a pilot study on the performance of Xpert MTB/RIF, 
MTBDRplus and Mycobacteria Growth Indicator Tube (MGIT) drug susceptibility testing methods 
for detection of rifampicin resistance in Lusaka, Zambia, at the Zambart Central Laboratory (ZCL). 
Methods
Ethical considerations
The study was approved by the University of Zambia biomedical research ethics committee 
(ref. no. 003-12-11) and all patients were requested to give written informed consent before 
participating in the study. The written informed consent was administered by study staff, and 
participants were given an opportunity to discuss the study before signing the informed consent 
form. To maintain confidentiality, each participant was allocated a unique study number that was 
used on all data collection tools, as well as for labelling of laboratory specimens. No names were 
used on any data collection tool. Informed consent forms and all study data were kept in secure 
cabinets with access limited to the principal investigator and the data manager. Paper-based case 
report forms were captured into secured, password-protected electronic databases.
Study Design 
The study was conducted between March 2012 and March 2014 on samples collected during an 
evaluation of Xpert MTB/RIF use in primary health care facilities in Lusaka, Zambia.6,7 Samples 
were collected from consecutive patients presenting to the primary health care facility who 
had rifampicin-resistant and rifampicin-indeterminate Xpert MTB/RIF results for confirmation of 
rifampicin resistance and for quality assurance in the ZCL. 
The performance of the Xpert© MTB/RIF and MTBDRplus assays for the detection of rifampicin 
resistant Mycobacterium tuberculosis was compared to culture-based drug susceptibility testing in 
30 specimens with rifampicin-resistant and rifampicin-indeterminate Xpert MTB/RIF results 
collected between March 2012 and March 2014. Xpert MTB/RIF and MTBDRplus were 100% 
sensitive and 100% concordant for rifampicin resistance detection, but 3 of 13 samples (23%) 
positive for rifampicin resistance on Xpert MTB/RIF and MTBDRplus were negative for rifampicin 
resistance on mycobacteria growth indicator tube drug susceptibility testing. Specificity was 72% 
for Xpert MTB/RIF and 80% for MTBDRplus. Positive predictive value for Xpert MTB/RIF for 
multidrug resistant tuberculosis was 47.8% for new patients and 77.8% for previously treated 
patients; negative predictive value was 100% for both new and previously treated patients. The 
discordant rifampicin resistance test results indicate a need to fully characterise circulating 
rifampicin resistant Mycobacterium tuberculosis strains in Zambia and to inform the development 
of guidelines for decision-making in relation to diagnosis of drug-resistant tuberculosis.
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Samples were transported to the central laboratory on the 
same day of collection or the following day and no 
preservatives were added. At the ZCL, the samples were 
decontaminated using the NaOH/NaLC method (2% NaOH 
for 20 minutes) and 0.5 mL of the pellet was inoculated into 
each of two manual MGIT tubes for primary isolation and 
identification of M. tuberculosis.; 0.5 mL was used to repeat 
the Xpert MTB/RIF test, and two drops were used to prepare 
a concentrated smear for fluorescent microscopy. 1.5 mL of 
the Xpert MTB/RIF sample reagent was added to 0.5 mL of 
the re-suspended pellet and Xpert MTB/RIF testing 
was performed as per standard procedure described by the 
manufacture.
Acid-fast bacilli positive cultures were identified using the 
capillia tuberculosis Neo assay (TAUNS Laboratories, Inc., 
Shizuoka, Japan) to confirm presence of Mycobacterium 
tuberculosis complex.8 Confirmed M. tuberculosis complex 
isolates were tested for drug sensitivity using the Becton 
Dickinson manual MGIT SIRE (streptomycin, isoniazid, 
rifampicin, ethambutol; Becton Dickinson, Bergen County, 
New Jersey, United States) drug susceptibility testing 
method and the MTBDRplus assay (version 1; HAIN Life 
Sciences, Nehren, Germany). The drug concentrations 
used were 1.0 µg/mL streptomycin, 0.1 µg/mL isoniazid, 
1.0 µg/mL rifampicin, and 5.0 µg/mL ethambutol. The 
MGIT SIRE tubes were read daily as per the manufacturer’s 
recommendation. To perform the MTBDRplus assay, 1 mL 
of broth from an M. tuberculosis complex culture-positive 
MGIT tube was used for DNA extraction using the 
genolyse method. Briefly, 1 ml of culture broth was 
centrifuged, the pellet was incubated for 5 minutes at 950C 
in lysis buffer after which a neutralisation buffer was 
added. Subsequent steps for polymerase chain reaction 
and hybridisation were followed as per standard procedure 
for MTBDRplus testing.9 All procedures included positive 
and negative controls.
The data were analysed using Stata version 13 (StataCorp 
LLC, College Station, Texas, United States). An initial 
descriptive analysis was done to determine the distribution 
of results, then the Xpert MTB/RIF results obtained at the 
primary health care setting were compared with the results 
obtained at the central laboratory. Further analysis was done 
to compare the performance of Xpert MTB/RIF, MTBDRplus 
and MGIT M. tuberculosis drug susceptibility testing and to 
determine the sensitivity and specificity of Xpert MTB/RIF 
and MTBDRplus compared to the gold standard MGIT 
culture for drug susceptibility testing.
Results
During the study period, 1070 patients had M. tuberculosis 
complex detected by the Xpert MTB/RIF test. Of these, 28 
(2.6%) were positive for rifampicin resistance and 15 (1.4%) 
had indeterminate rifampicin resistance results. Of the 43 
patients eligible for inclusion in the study (i.e. had rifampicin-
resistant or rifampicin-indeterminate Xpert MTB/RIF 
results), only 30 submitted samples for further testing at the 
central laboratory (Table 1). Of these, 21 (70%) were positive 
for both M. tuberculosis and rifampicin resistance, and nine 
(30%) were positive for M. tuberculosis but indeterminate for 
rifampicin resistance. On repeat Xpert MTB/RIF testing at 
the central laboratory, of the 21 patients initially positive 
for rifampicin resistance, 17 (81%) were again positive 
for rifampicin resistance, three (14%) were negative for 
rifampicin resistance and one (5%) tested negative for 
M. tuberculosis. 
Of the nine patients initially indeterminate for rifampicin 
resistance, five (56%) tested negative for rifampicin 
resistance and four (44%) tested negative for M. tuberculosis 
on repeat Xpert MTB/RIF testing (Table 1). These four 
(44%) samples negative for M. tuberculosis on repeat Xpert 
MTB/RIF testing were M. tuberculosis positive but 
rifampicin resistance negative when tested by both 
MTBDRplus and MGIT drug susceptibility testing (Tables 
2–3). Xpert MTB/RIF and MTBDRplus were 100% 
concordant for detection of rifampicin resistance (Table 2). 
When compared to MGIT drug susceptibility testing, the 
sensitivity of Xpert MTB/RIF and MTBDRplus for detection 
of rifampicin resistance was 100%, while specificity was 
72% for Xpert MTB/RIF and 80% for MTBDRplus. Three 
patients had positive rifampicin resistance results on both 
Xpert MTB/RIF and MTBDRplus (Table 2), but rifampicin 
resistance was not detected with MGIT drug susceptibility 
testing (Tables 3 and 4). On Xpert MTB/RIF all three 
samples showed no signal for probe D and on MTBDRplus, 
all were missing the wild-type 7 probe and showed no 
mutation probe (results not shown). These three isolates 
were also resistant to isoniazid on both MGIT drug 
susceptibility testing and MTBDRplus (Tables 3 and 4).
The overall positive predictive values and negative predictive 
values for MDR tuberculosis diagnosis for Xpert MTB/RIF 
compared to MGIT drug susceptibility testing were 62.5% 
and 100% and compared to MTBDRplus were 81.2% and 
100% (results not shown). For previously treated patients, the 
Xpert MTB/RIF positive predictive value was 77.8% and 
negative predictive value was 100%; for new patients, 
positive predictive value was 47.8% and negative predictive 
value was 100%. The MTBDRplus positive predictive value 
was 78.6% and negative predictive value was 100% compared 
to MGIT.
TABLE 1: Comparison of Xpert MTB/RIF testing at the primary health care facility 
peripheral laboratory to Xpert MTB/RIF testing at the central laboratory, Zambia, 
March 2012 and March 2014.
Primary laboratory 
Xpert MTB/RIF test 
result
Number Central laboratory repeat Xpert MTB/RIF test result 
Negative for 
M. tuberculosis
Not rifampicin 
resistant
Rifampicin 
resistant
Indeterminate 9 4 (44.4%) 5 (55.6%) 0
Rifampicin resistant 21 1 (4.8%) 3 (14.3%) 17 (81.0%)
Total 30 5 (16.7%) 8 (26.7%) 17 (56.6%)
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Discussion
Indeterminate rifampicin resistance results can be resolved 
by repeating the test, as shown in our study. Of all the samples 
that were initially indeterminate for rifampicin resistance, 
none tested positive on repeat testing. An indeterminate 
rifampicin resistance Xpert MTB/RIF result maybe due to 
low DNA quantity in the sample; this was supported by the 
high proportion of samples that were initially indeterminate 
that did not detect M. tuberculosis on repeat testing with Xpert 
MTB/RIF but were positive on M. tuberculosis culture. For 
prediction of MDR tuberculosis, our findings confirm that 
Xpert MTB/RIF has a low positive predictive value for MDR 
tuberculosis in low-prevalence MDR tuberculosis settings 
like Zambia, which has an estimated MDR prevalence of 
4.2%.10 Depending on Xpert MTB/RIF alone for diagnosis of 
MDR tuberculosis in our setting would lead to subjecting a 
significant proportion of patients to unnecessary second-line 
treatment.1
The performance of Xpert MTB/RIF and MTBDRplus were 
similar, which was expected since both are genotypic tests. 
The sensitivity of Xpert MTB/RIF for detection of rifampicin 
resistance was within the range of what has been reported by 
others, whereas the specificity of 73% was lower.11 The 
prevalence of silent rpoB gene mutations that do not confer 
phenotypic resistance determines the specificity of genotypic 
tests, if using a phenotypic test as a gold standard. While we 
were limited by a lack of capacity to sequence the three 
samples that had results suggesting false rifampicin 
resistance, other studies have reported false Xpert MTB/RIF 
or MTBDRplus rifampicin resistance caused by silent 
mutations in the rpoB gene.12,13,14,15,16 Further, these three 
isolates were also resistant to isoniazid on both MGIT drug 
susceptibility testing and MTBDRplus, consistent with the 
widely observed fact that in most cases, silent mutations in 
the rpoB gene are associated with mutations in the katG gene 
or promoter of the inhA gene.17,18 Probe D in the Xpert 
MTB/RIF and the wild-type 7 probe in MTBDRplus both 
target the same region of the rpoB gene, codon 526, which is 
one of the regions with known mutations that confer 
resistance to rifampicin. Detection of mutations in this region 
by both Xpert MTB/RIF and MTBDRplus shows strong 
evidence of the accuracy of our genotypic results. However, 
MGIT drug susceptibility testing has been shown to produce 
false susceptibility results for strains with minimal inhibitory 
concentrations for rifampicin close to the cut-off value of 
1 µg/mL used in MGIT drug susceptibility testing, or strains 
that have sub-critical minimal inhibitory concentrations for 
rifampicin.19 However, it is unlikely that the discordant 
results in our study were due to false susceptibility results 
for the MGIT drug susceptibility testing. To resolve these 
discrepant results, sequencing is required to determine the 
presence of silent mutations. However, lack of access to 
sequencing services was a limitation in our study.
This study was also limited by its small sample size but 
provides some insights into the comparable performance of 
Xpert MTB/RIF, MTBDRplus and culture drug susceptibility 
testing culture for the diagnosis of drug-resistant 
tuberculosis. There is an urgent need for Zambia to perform 
a full identification and classification of rpoB mutations and 
TABLE 2: Comparison of repeat Xpert MTB/RIF and MTBDRplus test results.
Repeat Xpert MTB/RIF test result Number MTBDRplus
Sensitive to isoniazid 
and rifampicin
Multidrug resistant Isoniazid resistant Rifampicin resistant No result
Rifampicin resistant 17 0 13 0 3 1
Not rifampicin resistant 8 8 0 0 0 0
Negative for M. tuberculosis 5 2 1 2 0 0
Total 30 10 14 2 3 1
TABLE 4: Comparison of MTBDRplus and mycobacterium growth indicator tube Mycobacterium tuberculosis drug susceptibility testing.
MTBDRplus result Number MGIT M. tuberculosis drug susceptibility testing
Sensitive to isoniazid 
and rifampicin
Multidrug resistant Isoniazid resistant Rifampicin resistant No result
Sensitive to isoniazid and rifampicin 10 10 0 0 0 0
Multidrug resistant 14 0 11 3 0 0
Isoniazid mono resistant 2 0 0 2 0 0
Rifampicin mono resistant 3 0 0 0 3 0
No result 1 0 0 0 0 1
Total 30 10 11 5 3 1
Abbreviations: MGIT, mycobacterium growth indicator tube. 
TABLE 3: Comparison of repeat Xpert MTB/RIF and mycobacterium growth indicator tube Mycobacterium tuberculosis drug susceptibility testing.
Repeat Xpert MTB/RIF test result Number MGIT M. tuberculosis drug susceptibility testing
Sensitive to isoniazid 
and rifampicin
Multidrug resistant Isoniazid resistant Rifampicin resistant No result
Rifampicin resistant 17 0 10 3 3 1
Not rifampicin resistant 8 8 0 0 0 0
Negative for M. tuberculosis 5 2 1 2 0 0
Total 30 10 11 5 3 1
Abbreviations: MGIT, mycobacterium growth indicator tube. 
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investigate minimal inhibitory concentrations for rifampicin, 
so as to optimise national guidelines for diagnosis of drug-
resistant tuberculosis. A thorough investigation of the 
performance of Xpert MTB/RIF and MTBDRplus for 
diagnosis of rifampicin resistance and prediction of MDR 
tuberculosis in the Zambian setting is recommended to 
avoid inappropriate treatment. Whole genome sequencing 
capacity is required to fully characterise circulating 
rifampicin-resistant M. tuberculosis strains. Improvements 
are needed to make these genotypic tests function as stand-
alone tests, as they offer the best prospects for early and 
accurate diagnosis for tuberculosis and MDR tuberculosis.
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